- Home
- Media Center
- Press releases
- Innovative Medicine
Innovative Medicine
U.S. FDA Grants Priority Review to Janssen’s New Drug Application for Chewable Mebendazole Tablets Intended to Treat Soil-Transmitted Helminthiasis
Johnson & Johnson shows ongoing commitment to London Declaration on NTDs through advancement of new chewable tablet
SIMPONI® Receives European Commission Approval for Treatment of Polyarticular Juvenile Idiopathic Arthritis
Health Authority Approval Marks Sixth Indication for SIMPONI in Europe
Ibrutinib (IMBRUVICA®) Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA) for the Development of a Treatment for Chronic Graft-Versus-Host Disease (cGVHD)
- In current clinical practice, there are no FDA-approved treatments for this life-threatening condition - FDA designation suggests potential use of ibrutinib beyond hematologic malignancies - The FDA also granted ibrutinib orphan drug designation for cGVHD
Johnson & Johnson Innovation and Janssen Research & Development Launch World Without Disease QuickFire Challenge
Largest QuickFire competition to date will award up to $500,000 in a research grant and entrance to Johnson & Johnson Innovation, JLABS, to promising transformational healthcare solution Challenge launched at 2016 BIO International Convention during the Bionic Innovation Forum
Janssen Presents New Data Showing INVOKANA® (canagliflozin) is Associated with Greater Blood Glucose Control and Treatment Adherence Compared to DPP-4 Inhibitors
Other Presentations at American Diabetes Association Scientific Sessions® Show INVOKANA® Therapy also is Associated with Achieving Blood Glucose and Blood Pressure Treatment Goals
New Phase 2 Proof-of-Concept Study Shows Canagliflozin Combination Therapy May Support Chronic Weight Management
Combination of Canagliflozin and Phentermine Demonstrates Improvements in Weight Management in Overweight or Obese Patients without T2DM
Daratumumab Significantly Extended Progression-Free Survival in Combination with Lenalidomide and Dexamethasone in Patients with Multiple Myeloma
- Data from Phase 3 MMY3003 (POLLUX) trial to be featured in the Presidential Symposium at the European Hematology Association (EHA) Annual Congress (Abstract LB2238) - Phase 3 MMY3004 (CASTOR) trial data will also be highlighted at EHA - Together, these results show the potential of daratumumab in combination with either a proteasome inhibitor or immunomodulatory agent
New Janssen Phase 3 Data in Patients with Moderately to Severely Active Rheumatoid Arthritis Shows Sirukumab Significantly Inhibited Radiographic Progression and Improved Signs and Symptoms of Disease
Sirukumab One-year Radiographic Data Show Significant Inhibition of Joint Destruction